Taken together these data indicate that AML with clonal SRSF2 mutations is vulnerable to inhibition of ATR, CHK1, and WEE1, while samples with co-occurring RUNX1 mutations were resistant. Here, RUNX1 is linked to acute myeloid leukemia.